Legend Biotech Balance Sheet Health
Financial Health criteria checks 4/6
Legend Biotech has a total shareholder equity of $1.3B and total debt of $281.3M, which brings its debt-to-equity ratio to 22.5%. Its total assets and total liabilities are $1.8B and $597.2M respectively.
Key information
22.5%
Debt to equity ratio
US$281.33m
Debt
| Interest coverage ratio | n/a |
| Cash | US$1.31b |
| Equity | US$1.25b |
| Total liabilities | US$597.24m |
| Total assets | US$1.85b |
Recent financial health updates
Is Legend Biotech (NASDAQ:LEGN) A Risky Investment?
Mar 06
Is Legend Biotech (NASDAQ:LEGN) A Risky Investment?
Nov 09Is Legend Biotech (NASDAQ:LEGN) Weighed On By Its Debt Load?
Apr 12Legend Biotech (NASDAQ:LEGN) Has Debt But No Earnings; Should You Worry?
May 14Is Legend Biotech (NASDAQ:LEGN) Weighed On By Its Debt Load?
Dec 30Recent updates
Legend Biotech: AdCom Documents Shed Light On Carvykti's Problems (Downgrade)
Mar 15Is Legend Biotech (NASDAQ:LEGN) A Risky Investment?
Mar 06Legend Biotech: Solid Traction With Carvykti Rollout
Jan 29Legend Biotech Corporation's (NASDAQ:LEGN) Share Price Not Quite Adding Up
Jan 16Is Legend Biotech (NASDAQ:LEGN) A Risky Investment?
Nov 09Is Legend Biotech (NASDAQ:LEGN) Weighed On By Its Debt Load?
Apr 12An Intrinsic Calculation For Legend Biotech Corporation (NASDAQ:LEGN) Suggests It's 44% Undervalued
Dec 14Legend Biotech wins approval of Carvykti for multiple myeloma in Japan
Sep 27Legend Biotech stock slides on proposed ADS offering
Jul 25Legend Biotech ends Phase 1 trial for lymphoma candidate
Jul 07News Flash: Analysts Just Made A Notable Upgrade To Their Legend Biotech Corporation (NASDAQ:LEGN) Forecasts
Jun 05Legend Biotech (NASDAQ:LEGN) Has Debt But No Earnings; Should You Worry?
May 14Here's What Analysts Are Forecasting For Legend Biotech Corporation (NASDAQ:LEGN) After Its Full-Year Results
Mar 22Legend Biotech: Carvykti Approval Makes For A Buy Opportunity
Mar 04Legend Biotech Corporation (NASDAQ:LEGN) Analysts Are More Bearish Than They Used To Be
Mar 03Is Legend Biotech (NASDAQ:LEGN) Weighed On By Its Debt Load?
Dec 30Calculating The Intrinsic Value Of Legend Biotech Corporation (NASDAQ:LEGN)
Nov 22Is Legend Biotech (NASDAQ:LEGN) Using Debt Sensibly?
Aug 26Analysts Have Just Cut Their Legend Biotech Corporation (NASDAQ:LEGN) Revenue Estimates By 18%
Jun 11Financial Position Analysis
Short Term Liabilities: LEGN's short term assets ($1.5B) exceed its short term liabilities ($216.4M).
Long Term Liabilities: LEGN's short term assets ($1.5B) exceed its long term liabilities ($380.8M).
Debt to Equity History and Analysis
Debt Level: LEGN has more cash than its total debt.
Reducing Debt: LEGN's debt to equity ratio has increased from 2.9% to 22.5% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: LEGN has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if LEGN has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.